Every SEC Form 3/4/5 on record for this filer (CIK 1911047) — 3 issuers, 15 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
This filer is an entity, not a person. This reporting owner's name carries a corporate/fund legal form, so it is an ENTITY filing under Section 16 — typically a fund with a board-designation right or a 10% holder — not an individual. Its 'director' rows are the entity's designation right, not a person's board seat.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | 10% owner | 2024-01-02 → 2025-01-02 | 10 | — |
| ENGN | enGene Therapeutics Inc. | 10% owner | 2023-11-02 → 2024-11-01 | 4 | $3M |
| FRBNU | Forbion European Acquisition Corp. | Director · lapsed | 2022-03-18 → 2023-10-31 | 4 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| ENGN | 2024-10-08 | Buy | 800 | $6.60 | $5,280 | 2,470,633 |
| ENGN | 2024-10-07 | Buy | 11,844 | $6.55 | $77,578 | 2,469,833 |
| ENGN | 2024-10-04 | Buy | 5,997 | $6.54 | $39,220 | 2,457,989 |
| ENGN | 2024-10-03 | Buy | 5,769 | $6.48 | $37,383 | 2,451,992 |
| ENGN | 2024-10-02 | Buy | 10,153 | $6.37 | $64,675 | 2,446,223 |
| ENGN | 2024-10-01 | Buy | 35,279 | $6.44 | $227,197 | 2,436,070 |
| ENGN | 2024-09-30 | Buy | 341,332 | $6.34 | $2M | 2,400,791 |
| ENGN | 2024-09-27 | Buy | 3,243 | $6.38 | $20,690 | 2,059,459 |
| ENGN | 2024-09-27 | Buy | 38,396 | $5.94 | $228,072 | 2,056,216 |
| ENGN | 2023-12-29 | Buy | 9,620 | $9.09 | $87,446 | 2,017,820 |
1 of 3 issuers are covered and open a security page; the rest are on file here only.
